Compare Ascendis Pharma A/S (ASND) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Dover Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Dover Corp trades at $214.05 (market cap $29.00B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays a 0.97% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DOV | |
|---|---|---|
Market Cap | $17.74B | $29.00B |
Sector | Health | Industrials |
52-Week High | $277.18 | $233.31 |
52-Week Low | $163.32 | $161.16 |
Enterprise Value | $18.11B | $30.64B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Dover Corporation (DOV) trades at $215.33, up 1.78% today, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights product launches in data center and industrial solutions, supporting revenue growth. The stock is supported by a high analyst buy consensus and a $251 price target, though technical indicators show resistance near $214.
Outlook is positive with robust profitability and analyst optimism, but risks include market volatility and execution challenges. The stock offers value through earnings growth and dividend yield, with upside potential if it breaks resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
